Search Results

Once we recognized that shared landscape, the connection between Lupus Colorado and the Community Access With CANN's assistance, Lupus Colorado facilitated a community roundtable discussion and advocacy day at the Colorado state capitol, bringing together patient advocates from across the spectrum of chronic Lupus Colorado eventually became a kind of testing ground for patient engagement around these issues. It surprised all of us how quickly Louisiana and Colorado began to feel connected through shared purpose

Despite this, one such policy being considered by the Colorado PDAB and similar boards in other states At a recent meeting of Colorado PDAB stakeholders, following the board's unanimous approval of the list Ten states including Colorado have already established PDABs, and many others are following suit. Colorado is home to more than 13,000 people living with HIV and has been at the forefront of combating Colorado's PDAB, as it currently stands, falls short of that.

Editor's Note: This article was originally published on April 10, 2026, by Lupus Colorado and is republished Lupus Colorado, led by CEO Kristy Kibler, works to improve the lives of people affected by lupus through advocacy, education, and support services across Colorado. To learn more about Lupus Colorado or donate to support their work, visit LupusColorado.org. At Lupus Colorado, we see every day that investing in people drives lasting change.

In spite of this, Colorado and Maryland, two states that have set UPLs, did not engage in any interdepartmental Furthermore, in Colorado in particular, there was no concrete analysis defining desired budgetary goals Colorado set a UPL for Enbrel based on the federal government’s Maximum Fair Price (MFP) it had negotiated Colorado is currently involved in litigation involving Amgen, presently preventing any implementation The recent ruling in the litigation between Amgen and Colorado, in which the state PDAB set a UPL on

Colorado's PDAB situation is particularly egregious. Yet Colorado PDAB staff have consistently avoided conducting a proper fiscal impact analysis, bluntly The Colorado PDAB's actions exemplify how these bureaucratic decisions create genuine fear and uncertainty At least one pharmaceutical company has already threatened to pull drugs from Colorado if price caps From Maryland's last-minute document dumps to Colorado's refusal to conduct impact analyses and Oregon's

nine (9) states that had, have or are in the process of enacting PDAB legislation: Washington, Oregon, Colorado For example, Colorado’s is associated with the Division of Insurance, and Oregon’s is associated with The number of drugs to be selected annually for review also varies, such as Colorado with five and Oregon The New Jersey DPAB advisory council has twenty-seven (27) members, while Colorado’s has fifteen (15) currently have the ability to enact binding upper payment limit (UPL) settings: Washington, Oregon, Colorado

Additionally, in Colorado and Massachusetts, while Hispanic Americans do not account for the majority In Colorado, Hispanic Americans constitute for 22% of the state’s population but account for 34.8% of MPV diagnoses (Colorado Department of Public Health, 2022). Colorado Monkeypox Data. Colorado Department of Public Health: Diseases A to Z: Monkeypox. https://cdphe.colorado.gov/diseases-a-to-z

The Colorado data is presented in two rows: “CO-E” represents the 343 drugs eligible for review, and In Colorado, 97.4% of the drugs initially eligible for review by the PDAB treat conditions categorized In Colorado, the most frequently targeted categories include cancer, genetic disorders, autoimmune disorders In Colorado, the PDAB has already conducted affordability reviews on Enbrel and Stelara, two drugs used

Kristy Kibler, CEO of Lupus Colorado, details the issue: "Small, state level patient groups are drowning Kristy from Lupus Colorado articulates what advocacy leaders want: "I would want to know what barriers These creative advocates—like Kristy in Colorado working directly with lupus patients, or Warren serving

Trikafta was selected by Colorado's Prescription Drug Affordability Board (PDAB) for "affordability review Back in Colorado, Trikafta patient Amanda Boone testified to the Board about her fear of losing the ability similar backdoor QALY insertions and by ICER’s Harvard equivalent, PORTAL – all funded by the state of Colorado

While Colorado, Ohio, New York, and West Virginia addressed the issue of additional restrictions or a

The next meeting CANN will be attending is virtual for the state of Colorado, on July 13th at 10am Mountain